References
- Naka K, Hoshii T, Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 2010;101:1577–1581.
- Corbin AS, Agarwal A, Loriaux M, . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011;121:396–409.
- Hu Y, Chen Y, Douglas L, . Beta-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009;23: 109–116.
- Li YF, Deng ZK, Xuan HB, . Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy. Chin Med J (Engl) 2009;122:1413–1417.
- Li YF, Liu X, Liu DS, . The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy. Leuk Lymphoma 2009;50: 1889–1891.
- Stone RM, Donohue KA, Stock W, . A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol 2009;63:859–864.
- Quintás-Cardama A, Kantarjian H, Garcia-Maner G, . Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109: 248–255.
- Chen Y, Hu Y, Michaels S, . Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009;23:1446–1454.
- Wetzler M, Segal D. Omacetaxine as an anticancer therapeutic: what is old is new again. Curr Pharm Des 2011;17:59–64.
- Guilhot F, Apperley J, Kim DW, . Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib resistant or intolerant chronic myeloid leukemia in accelerated phase. Blood 2007;109:4143–4150.
- Alvarado Y, Kantarjian H, O'Brien S, . Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009;15:3709–3718.
- Minami Y, Stuart SA, Ikawa T, . BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci USA 2008;105:17967–17972.
- Stuart SA, Minami Y, Wang JY. The CML stem cell: evolution of the progenitor. Cell Cycle 2009;8:1338–1343.
- Jamieson CH, Ailles LE, Dylla SJ, . Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657–667.
- Belloc F, Airiau K, Jeanneteau M, . The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. Leukemia 2009;23:679–685.
- Kim KI, Park J, Ahn KS, . Molecular characterization and prognostic significance of FLT3 in CML progression. Leuk Res 2010;34:995–1001.
- Vidović A, Janković G, Colović M, . The proto-oncogene expression varies over the course of chronic myeloid leukemia. Hematology 2008;13:34–40.
- Li YF, Zhang ST. The effect of homoharringtonine on telomerase activity of CD34 cells from chronic myelogenous leukemia. J Leuk Lymphoma (Chin) 2004;13:42–43.